
CTO @FormationBio. Building AI-native biopharma. Neuroscience / ML PhD. Dad of two girls.
Joined February 2009
- Tweets50
- Following56
- Followers36
- Likes10
Dan Neil retweeted
One of the world's largest companies will be one that helps you live longer and healthier. Really enjoyed reading this deep dive by @a16z on how AI will reshape Pharma! @vintweeta @aleximm @CarolineGoggs
Dan Neil retweeted
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @formationbio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - a step in its plan to make drug development more efficient and become 'the next pharma'. @BenjamineYLiu
Watch the full video: biotechtv.com/post/formation…
We're hiring for engineering and PM-shaped roles to help us continue to improve how we run clinical trials. You'll be embedded directly with our experienced clinical operations teams and get firsthand exposure on how trials are run.
Ideally, you are entrepreneurial, high-agency, and technical. Ex-founders (or current founders) are welcome. Experience in health/regulated industries is helpful.
Great opp for anyone who wants to start a company in the clinical trial space in the future :).
DM me if you think you're a fit!
Dan Neil retweeted
Formation raises $600 million to fix AI's biotech bottleneck axios.com/2026/10/29/formati…
Dan Neil retweeted
Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund.
@lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development.
As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients.
Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.
Dan Neil retweeted
(1/3) Phyla is Formation Bio’s context layer for causal biology. We benchmarked it against Claude Science and GPT-Rosalind on writing full research dossiers for 7 drug target–disease pairs, and the results are in. 99.7% of Phyla’s statements carried a citation, compared to Claude Science: 87% (Claude Science) and 86% (GPT-Rosalind). Phyla never dropped below 99.3% on any pair.
"In a world of drug discovery abundance, the scarce capability is no longer making drugs, but rather, knowing which drugs are worth developing."
@BenjamineYLiu, co-founder and CEO of Formation Bio, explains how AI will transform the economics of the pharma industry - link in replies
Kenny points out how the future of AI-native companies may be built on 55-year-old ideas. Our Principal Engineer explores why Unix - small tools, composable systems, and text as a universal interface - offers a powerful blueprint for building technology in the age of AI.
In his latest blog, our Principal Engineer Kenny Peng revisits the Unix philosophy (do one thing well, compose freely, shared interfaces) as a blueprint for agentic system design.
Using biopharma as the test case, he breaks down why hardcoded pipelines break down over time, and what composable alternatives require. Read here: linkedin.com/posts/kpeng_the…
2
34
Dan Neil retweeted
Excited to share that Mike Ehlers is joining @formationbio as Chief Scientific Officer and Head of R&D. Over the course of his career as a scientist, drug developer, and investor, Mike has advanced 40+ drugs into the clinic, with approvals spanning Alzheimer's, ALS, MS, hemophilia, and SMA. Welcome to the team, Mike!
Dan Neil retweeted
Drug development is one of the highest-stakes place for AI to drive meaningful outcomes for people. Mike joining Formation Bio, given his track record in pharma, is real world proof of that thesis. In the AI era, expert judgment matters more, not less. Excited for him to bring his expertise and scientific leadership to the team at Formation.
Excited to share that Mike Ehlers is joining @formationbio as Chief Scientific Officer and Head of R&D. Over the course of his career as a scientist, drug developer, and investor, Mike has advanced 40+ drugs into the clinic, with approvals spanning Alzheimer's, ALS, MS, hemophilia, and SMA. Welcome to the team, Mike!
AI-native is a term a lot of companies use, but few can show you what it really looks like. Last week, the entire company shipped software: scientists, ops, clinicians, HR, marketing... many for the first time. Building on the data platform and tech stack our engineers have spent years developing, everyone was shipping practical tools in days.
AI is moving fast. Raising the floor on what every team can build, not just engineers, is how @formationbio is creating and leading the pharma company of the future. Link to our open roles in comments.
Dan Neil retweeted
Last week, Formation Bio CTO @dan_neil joined the @AWS Life Sciences Symposium reception panel alongside leaders from @Lux_Capital, @abbvie, and @AstraZeneca. With the conversation focused on innovation, Dan spoke about how one of the biggest bottlenecks facing drug development is actually organizational, and fixing this starts with how institutional knowledge is built and kept.
At Formation Bio, we build so that every program makes the next one smarter. Read more about Dan's thinking here: formation.bio/blog/building-…
Dan Neil retweeted
The world has more promising discovered drug candidates than ever. The problem is developing them. We built Formation Bio to fix that, using AI to develop drugs faster and with a higher likelihood of success.
Thank you @amyfeldman and @Forbes telling the story of our mission, and our vision for the future of pharma.
forbes.com/sites/amyfeldman/…
Dan Neil retweeted
Great to see our CDO Gavin Corcoran in action on Monday at the Chief Medical Officer 360º Summit, by @FierceBiotech, exploring how we use AI to enhance clinical development. Gavin spoke about how real impact comes from AI systems that let you reimagine entire workflows, not just augment individual people within an old workflow.
Learn more about our approach: formation.bio/blog

















